Bastian Dehmel

Corporate Officer/Principal bij OCULIS HOLDING AG

54 jaar

Health Technology

Consumer Services

Actieve functies van Bastian Dehmel

Bedrijven	Functie	Begin	Einde
OCULIS HOLDING AG	Corporate Officer/Principal	01-01-2022	-

Bedrijven	Functie	Begin	Einde
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Hoofd Techniek/Wetenschap/O&O	01-10-2017	01-12-2021
Amgen (Europe) GmbH	Corporate Officer/Principal	01-12-2013	01-07-2017

Freie Universität Berlin

Doctorate Degree

Internationaal

Operationeel

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Doctorate Degree	1

Sectoraal

Health Technology	3
Consumer Services	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
OCULIS HOLDING AG	Health Technology

Bedrijven in privébezit	2
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology
Amgen (Europe) GmbH

Bedrijven in privébezit

Health Technology

Amgen (Europe) GmbH